Evolent Health announced Q3 2026 revenue of $725.4 million, up from $479.5 million in Q3 2025, driven by client renewals and oncology service expansions. The company reduced its net loss margin to 3.2% from 5.6% and reported adjusted EBITDA of $34.3 million. Evolent also renewed key contracts and expanded oncology services to new states, expecting its AI platform and oncology solutions to fuel future growth. It raised its full-year 2026 revenue guidance to $2.6-$2.7 billion and adjusted EBITDA guidance to $130-$135 million, signaling confidence in operational performance despite ongoing healthcare cost pressures.
Evolent's Q3 2026 results provide context for readers following healthcare developments. For readers following the health sector, here is Pluang's market snapshot as of Nov 05, 2026 19:01 WIB: out of 150 priced US health stocks, 94 rose and 48 fell. Among notable movers, ADPT gained 4.79% to USD 27.99 with 100% buy orders and a typical hold time of 37 days, contrasting with BKD which dropped 4.47% to USD 10.69 and TAK which rose 3.51% to USD 21.80 but saw 100% sell orders and a shorter hold time of 18 days.
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Berkshire Hathaway's stock portfolio is now worth about three times what the company originally paid for it. These gains alone represent roughly 19% of Berkshire Hathaway's total company value, highlighting the significant growth and value generated ...
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
Firmly secured $15 million in a Series A funding round led by Squarepoint Capital, with participation from J.P. Morgan Payments, Mastercard, and Samsung NEXT. The company provides a no-code platform that connects merchants to AI-driven shopping chann...
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
